Sarepta price target raised to $150 from $148 at Guggenheim

Nov 7, 2024 · Guggenheim raised the firm’s price target on Sarepta (SRPT) to $150 from $148 and keeps a Buy rating on the shares. Elevidys and exon-skipping franchise sales were above …

$150
OFF

Sarepta Price Target Raised To $150 From $148 At Guggenheim

2 weeks from now

Nov 7, 2024 · Guggenheim raised the firm’s price target on Sarepta (SRPT) to $150 from $148 and keeps a Buy rating on the shares. Elevidys and exon-skipping franchise sales were above …

nasdaq.com

$148.00
OFF

Guggenheim Issues Positive Forecast For Sarepta Therapeutics …

2 weeks from now

Nov 10, 2024 · Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price target raised by Guggenheim from $148.00 to $150.00 in a research report released on Thursday, Benzinga …

mayfieldrecorder.com

$148.00
OFF

Recent Research Analysts’ Ratings Updates For Sarepta …

2 weeks from now

11/7/2024 – Sarepta Therapeutics had its price target raised by analysts at Guggenheim from $148.00 to $150.00. They now have a “buy” rating on the stock.

americanbankingnews.com

$148.00
OFF

Analysts Set Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Target …

2 weeks from now

Dec 10, 2024 · Guggenheim upped their price target on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a research report on Thursday, …

etfdailynews.com

$179.00
OFF

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives ... - MarketBeat

2 weeks from now

Evercore ISI decreased their price objective on Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating for the company in a report on Thursday, November 7th. …

marketbeat.com

$150
OFF

Sarepta Recent Weakness Brings Buying Opportunity, Says JPMorgan

2 weeks from now

Nov 12, 2024 · Sarepta price target raised to $150 from $148 at Guggenheim Sarepta price target lowered to $193 from $200 at Baird Sarepta price target raised to $209 from $203 at Barclays …

yahoo.com

$148.00
OFF

Simplify Asset Management Inc. Buys 88,474 Shares Of Sarepta ...

2 weeks from now

Nov 15, 2024 · Guggenheim raised their price target on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a "buy" rating in a report on Thursday, November 7th.

marketbeat.com

$148
OFF

Guggenheim Maintains Buy On Sarepta Therapeutics, Raises Price …

2 weeks from now

Guggenheim analyst Whitney Ijem maintains Sarepta Therapeutics (NASDAQ: SRPT) with a Buy and raises the price target from $148 to $150.

webull.com

$148.00
OFF

HC Wainwright Reiterates Sell Rating For Sarepta ... - Defense World

2 weeks from now

Dec 21, 2024 · Finally, Guggenheim upped their price target on Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a report on Thursday, November 7th.

defenseworld.net

$148.00
OFF

Needham & Company LLC Lowers Sarepta Therapeutics …

2 weeks from now

Dec 1, 2024 · Guggenheim increased their price target on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, …

defenseworld.net

$148.00
OFF

Eagle Asset Management Inc. Lowers Stake In Sarepta

2 weeks from now

Nov 23, 2024 · Guggenheim boosted their target price on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a "buy" rating in a research report on Thursday, …

marketbeat.com

$209.00
OFF

Buy Rating For Sarepta Therapeutics: Significant Pipeline Potential …

2 weeks from now

Nov 20, 2024 · Analyst Luke Sergott of Barclays maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price target of $209.00.

businessinsider.com

$178.71
OFF

Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

2 weeks from now

2 days ago · SRPT's current price target is $178.71. Learn why top analysts are making this stock forecast for Sarepta Therapeutics at MarketBeat.

marketbeat.com

$200.00
OFF

Sarepta Therapeutics: Strong Market Position And Growth …

2 weeks from now

Nov 19, 2024 · In a report released yesterday, Kostas Biliouris from BMO Capital maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price target of $200.00.

businessinsider.com

$148.00
OFF

Needham & Company LLC Cuts Sarepta Therapeutics …

2 weeks from now

Nov 27, 2024 · Finally, Guggenheim boosted their price target on Sarepta Therapeutics from $148.00 to $150.00 and gave the company a "buy" rating in a research report on Thursday, …

marketbeat.com

$80
OFF

Sarepta Initiated With A Sell At H.C. Wainwright

2 weeks from now

Nov 25, 2024 · H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Sarepta (SRPT) with a Sell rating and $80 price target The firm considers Elevidys consensus estimates to be too …

businessinsider.com

FAQs about Sarepta price target raised to $150 from $148 at Guggenheim Coupon?

Should you buy Sarepta Therapeutics (SRPT)?

In a report released yesterday, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price target of $210.00. Tazeen Ahmad has given his Buy rating due to a combination of factors that underline the potential growth and strong market position of Sarepta Therapeutics. ...

Why has Tazeen Ahmad rated Sarepta Therapeutics a buy?

Tazeen Ahmad has given his Buy rating due to a combination of factors that underline the potential growth and strong market position of Sarepta Therapeutics. One of the key reasons is the anticipated success of Sarepta’s gene therapy, Elevidys, despite the emerging data from a competitor, RegenxBio. ...

Should you buy Sarepta (SRPT) shares?

JPMorgan sees a long-term buying opportunity after Sarepta (SRPT) shares were under pressure last week post earnings. Near-term, if one believes that Sarepta is being overly conservative on Q4 Elevidys product guidance, current share levels offer a compelling buying opportunity, the analyst tells investors in a research note. ...